**Supplementary File 1.** Criteria for Defining Cardiotoxicity Scores and Binning Compounds Used to Establish Deep Learning Models

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Cardiotoxicity Score** | **Description** | **Drug and****Condition Rangea** | **Effect on Contractility** | **Sarcomere Damage** | **Nuclear Count** |
| Class 3 | Highly toxic | Bortezomib: 1 μM, 3 μM, 10 μMDoxorubicin: 1 μM, 3 μM, 10 μMGivinostat: 3 μM, 10 μMBafilomycin: 1 μM, 3 μM, 10 μMPaclitaxol: 10 μM | Increase or decrease in beat rate > 30%Displacement reduced by > 50%Contraction velocity reduced by > 50% | No visible Z-disk, or highly damaged sarcomere present | < 20% cell survival by nuclear count |
| Class 2 | Toxic | Bortezomib: 0.03 μM, 0.1 μM, 0.3 μMCisapride: 1 μM, 3 μM, 10 μMSorafenib: 10 μMGivinostat: 1 μMBafilomycin: 0.01 μM, 0.03 μM, 0.1 μM, 0.3 μMPaclitaxol: 3 μMJQ1: 10 μM | No significant effect on beat rateDisplacement reduced by > 35%Contraction velocity reduced by > 35% | Visibly damaged sarcomeres |  < 60% cell survival by nuclear count |
| Class 1 | Mildly toxic | Bortezomib: 0.01 μMDoxorubicin: 0.3 μMCisapride: 0.3 μMGivinostat: 0.3 μMPaclitaxol: 1 μMJQ1: 1 μM, 3 μM | No significant effect on beat rateNo significant effect on displacementNo significant effect on contraction velocity | Subtle damage to sarcomeres, not easily quantifiable | No significant effect on nuclear count |
| Class 0b | Non-toxic | DMSO (0.1%) | No significant effect | No significant effect | No significant effect |

DMSO, dimethyl sulfoxide.

aEach drug concentration was binned to these classes based on three criteria: functional effects on contractility, extent of sarcomere damage, and number of surviving cells (nuclear count).

bDMSO-treated (0.1%) condition.